BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $5.16, but opened at $5.36. BioCryst Pharmaceuticals shares last traded at $5.16, with a volume of 1,660,424 shares traded.
BCRX has been the topic of several research analyst reports. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, September 3rd. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. J P Morgan Chase & Co raised shares of BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $6.00 to $9.00 in a research note on Tuesday, September 5th. Jefferies Group LLC raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the company from $5.00 to $7.00 in a research note on Wednesday, September 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $9.13.
The firm’s market cap is $415.81 million. The stock’s 50 day moving average price is $4.85 and its 200-day moving average price is $6.10.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.22) EPS. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post ($0.75) EPS for the current year.
A number of hedge funds have recently made changes to their positions in BCRX. RA Capital Management LLC lifted its holdings in BioCryst Pharmaceuticals by 47.9% in the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after purchasing an additional 1,672,447 shares in the last quarter. FMR LLC lifted its holdings in BioCryst Pharmaceuticals by 114.5% in the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock valued at $17,373,000 after purchasing an additional 1,667,791 shares in the last quarter. Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 49.1% in the 1st quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock valued at $42,098,000 after purchasing an additional 1,651,292 shares in the last quarter. State Street Corp lifted its holdings in BioCryst Pharmaceuticals by 72.0% in the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after purchasing an additional 1,636,909 shares in the last quarter. Finally, Bogle Investment Management L P DE purchased a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $9,058,000. Institutional investors own 86.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/14/biocryst-pharmaceuticals-inc-bcrx-shares-gap-up-to-5-36.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.